Cargando…

Population Exposure‐Response Modeling of Naloxegol in Patients With Noncancer‐Related Pain and Opioid‐Induced Constipation

Naloxegol is a polyethylene glycol derivative of naloxone approved in the US as a once‐daily oral treatment for opioid‐induced constipation (OIC) in adults with chronic noncancer pain. Population exposure–response models were constructed based on data from two phase III studies comprising 1,331 adul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al‐Huniti, N, Nielsen, JC, Hutmacher, MM, Lappalainen, J, Cantagallo, K, Sostek, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961079/ https://www.ncbi.nlm.nih.gov/pubmed/27435972 http://dx.doi.org/10.1002/psp4.12099

Ejemplares similares

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation
por: Al‐Huniti, Nidal, et al.
Publicado: (2017)

Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation
por: Floettmann, Eike, et al.
Publicado: (2017)

Simulation and Prediction of the Drug‐Drug Interaction Potential of Naloxegol by Physiologically Based Pharmacokinetic Modeling
por: Zhou, D, et al.
Publicado: (2016)

Clinical utility of naloxegol in the treatment of opioid-induced constipation
por: Bruner, Heather C, et al.
Publicado: (2015)

Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Constipation in Elderly Patients with Noncancer Pain: Focus on Opioid-Induced Constipation
por: Chokhavatia, Sita, et al.
Publicado: (2016)

Correction to: Effectiveness of naloxegol in patients with cancer pain suffering from opioid‑induced constipation
por: Lemaire, Antoine, et al.
Publicado: (2021)

Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients’ Health State Utility
por: Lawson, Richard, et al.
Publicado: (2016)

Evaluating the Safety and Efficacy of Naloxegol in Critically Ill Opioid-Induced Constipation Patients
por: Rizwan, M. Zeeshan, et al.
Publicado: (2023)

Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation
por: Anantharamu, Tejus, et al.
Publicado: (2015)

Naloxegol in opioid-induced constipation: a new paradigm in the treatment of a common problem
por: Yoon, Stephanie C, et al.
Publicado: (2017)

Safety of oral methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Rauck, Richard L, et al.
Publicado: (2018)

Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain
por: BouSaba, Joelle, et al.
Publicado: (2022)

Satisfaction with Therapy Among Patients with Chronic Noncancer Pain with Opioid-Induced Constipation
por: LoCasale, Robert J., et al.
Publicado: (2016)

A Randomized Study of Lubiprostone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain
por: Cryer, Byron, et al.
Publicado: (2014)

Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain
por: Viscusi, Eugene R.
Publicado: (2019)

Absorption, distribution, metabolism, and excretion of [(14)C]-labeled naloxegol in healthy subjects
por: Bui, Khanh, et al.
Publicado: (2015)

A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation—The NACASY Study
por: Davies, Andrew, et al.
Publicado: (2022)

Efficacy and Safety of Prucalopride in Patients with Chronic Noncancer Pain Suffering from Opioid-Induced Constipation
por: Sloots, Cornelius E. J., et al.
Publicado: (2010)

A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain
por: Jamal, M Mazen, et al.
Publicado: (2015)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2015)

Peripherally acting μ-opioid receptor antagonists as treatment options for constipation in noncancer pain patients on chronic opioid therapy
por: Pergolizzi, Joseph V, et al.
Publicado: (2017)

Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain
por: Webster, Lynn R, et al.
Publicado: (2018)

Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain [Corrigendum]
Publicado: (2018)

Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis
por: Cobo Dols, Manuel, et al.
Publicado: (2021)

Naloxegol to Prevent Constipation in ICU Adults Receiving Opioids: A Randomized Double-Blind Placebo-Controlled Pilot Trial
por: Duprey, Matthew S., et al.
Publicado: (2022)

Effect of Naloxegol on Opioid-Induced Esophageal Motility Disorder
por: Ulteig, Crista, et al.
Publicado: (2022)

Efficacy and Safety of Methylnaltrexone for Opioid-Induced Constipation in Patients With Chronic Noncancer Pain: A Placebo Crossover Analysis
por: Viscusi, Eugene R., et al.
Publicado: (2016)

Naldemedine in Japanese patients with opioid-induced constipation and chronic noncancer pain: open-label Phase III studies
por: Saito, Yoji, et al.
Publicado: (2018)

European clinical practice recommendations on opioids for chronic noncancer pain – Part 1: Role of opioids in the management of chronic noncancer pain
por: Häuser, Winfried, et al.
Publicado: (2021)

Incidence and Health Related Quality of Life of Opioid-Induced Constipation in Chronic Noncancer Pain Patients: A Prospective Multicentre Cohort Study
por: Veiga, Dalila R., et al.
Publicado: (2018)

Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy
por: Stern, Emily K, et al.
Publicado: (2018)

Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction
por: Poulsen, Jakob Lykke, et al.
Publicado: (2014)

Opioid Pharmacotherapy for Chronic Noncancer Pain: The American Experience
por: Chapman, C. Richard
Publicado: (2013)

Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone
por: Webster, Lynn R, et al.
Publicado: (2018)

When People with Opioid-Induced Constipation Speak: A Patient Survey
por: Epstein, Robert S., et al.
Publicado: (2017)

Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies
por: Chey, William D, et al.
Publicado: (2023)

A Randomized, Multicenter, Prospective, Crossover, Open-Label Study of Factors Associated With Patient Preferences for Naloxegol or PEG 3350 for Opioid-Induced Constipation
por: Brenner, Darren M., et al.
Publicado: (2019)

Chronic Noncancer Pain and Opioid Addiction: Diagnostic and Management Challenges
por: Kathiresan, Preethy, et al.
Publicado: (2020)

Patient Preferences for Change in Symptoms Associated with Opioid-Induced Constipation
por: Epstein, Robert S., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5rlvkib3ds7trd9gngruq2c19g